1. The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study
- Author
-
Albert Martínez-Pinteño, Gisela Mezquida, Miquel Bioque, Jose M López-Ilundain, Álvaro Andreu-Bernabeu, Iñaki Zorrilla, Anna Mané, Roberto Rodríguez-Jiménez, Iluminada Corripio, Salvador Sarró, Ángela Ibáñez, Judith Usall, Olga Rivero, Patricia Gassó, Juan Carlos Leza, Manuel J Cuesta, Mara Parellada, Ana González-Pinto, Esther Berrocoso, Sergi Mas, Miguel Bernardo, S Amoretti, C Morén, E Urbiola, J González-Peñas, A Roldán, A Catalán, I González-Ortega, A Toll, T Legido, L Sanchez-Pastor, M Dompablo, E Pomarol-Clotet, Landín-Romero R, A Butjosa, E Rubio, null Lorente-OmeñacaR, M Ribeiro, I López-Torres, L León-Quismondo, J Nácher, F Contretas, A Lobo, M Gutiérrez-Fraile, and PA Sáiz
- Subjects
recurrent disease ,correlation analysis ,nerve growth factor ,Article ,remission ,male ,Recurrence ,Nerve Growth Factor ,follow up ,Humans ,Pharmacology (medical) ,controlled study ,human ,Longitudinal Studies ,Biological Psychiatry ,Pharmacology ,relapse ,predictive value ,Prevention ,adult ,Brain-Derived Neurotrophic Factor ,neurotrophin ,longitudinal study ,scoring system ,protein function ,biological marker ,cohort analysis ,major clinical study ,First-episode schizophrenia ,schizophrenia ,Psychiatry and Mental health ,female ,Neurology ,Nerve growth factor (NGF) ,brain derived neurotrophic factor ,disease severity assessment ,protein blood level ,symptomatology ,Schizophrenia ,Peripheral biomarker ,Brain-derived neurotrophic factor (BDNF) ,Neurology (clinical) ,Positive and Negative Syndrome Scale ,Biomarkers - Abstract
Neurotrophins have been proposed to be involved in biological mechanisms which might underlie different clinical outcomes in schizophrenia. The aims of the present study were to examine the BDNF/NGF plasma levels in a cohort of first-episode schizophrenia (FES) patients in remission as potential biological predictors of relapse; to study the associations between these neurotrophins and the symptomatology severity through different stages after a FES in two independent cohorts. 2EPs-Cohort: 69 first-episode in clinical remission were included. BDNF/NGF plasma levelsand symptom severity were measured at enrollment and at 3-year or at the time of the second episode/relapse. FLAMM-PEPs-Cohort: 65 first-episodes were also included. BDNF/NGF and symptom severity were obtained at enrollment and 2-year follow-up. Symptomatology was assessed with the Marder-PANSS-Factor scores. Plasma neurotrophins did not differ significantly over time and neither BDNF/NGF were predictors of relapse. Besides, in remission stages, baseline BDNF levels showed significant correlations with both positive and negative symptoms (p
- Published
- 2022